埃托米达的应用和制药发展:挑战和战略
Hao Zhang1,2, Ailing Wu3,4, Xichen Nan1
1School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, People's Republic of China.
麻醉剂埃托米达提供了血液动力学稳定性,但面临着溶解性和上腺抑制等副作用的挑战. 研究药物设计和有针对性的输送策略,以改进埃托米达制剂并扩大其临床用途.
科学领域:
- 麻醉学 麻醉学
- 药理学 药理学是指药理学的学科.
- 药物运输 药物运输 药物运输
背景情况:
- 埃托米达是一种合成的伊米达麻醉剂,作用于GABA受体,以血液动力学稳定性和最小的呼吸抑制而闻名.
- 尽管有优点,但埃托米达的低水溶性和副作用 (上皮层抑制,肌细胞结核) 限制了其临床应用.
- 现有的埃托米达制剂尚未完全消除其有毒副作用.
研究的目的:
- 审查用于埃托米达的制药设计策略.
- 建议针对新型埃托米达制剂进行有针对性的研究.
- 讨论扩大埃托米达使用的施用途径和剂量形式.
主要方法:
- 关于埃托米达特性的文献综述和药物输送研究.
- 对麻醉剂的制药设计原则的分析.
- 探索潜在的注射途径和剂量形式.
主要成果:
- 鉴定了当前埃托米达特配方在解决副作用方面的局限性.
- 突出了先进药物设计的潜力,以减轻毒性.
- 讨论了各种传递系统的可行性,以改善埃托米达治疗.
结论:
- 制药设计有望克服埃托米达的局限性.
- 对新型制剂和输送途径进行有针对性的研究至关重要.
- 进一步开发可以扩大etomidate的治疗应用.
更多相关视频
08:49Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
Published on: October 16, 2013
05:42Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
Published on: January 7, 2019
相关概念视频
Parenteral Anesthetics: Overview
Preclinical Development: Overview
Drug Regulation
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinical Trials: Overview
